Cosciens Biopharma Inc. has acquired Nualtis for an undisclosed amount. This corporate acquisition integrates Nualtis, a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, into Cosciens Biopharma Inc.'s operations. The transaction expands Cosciens Biopharma Inc.'s capabilities in advanced drug delivery solutions.
Nualtis specializes in superior film technologies, including VersaFilm® and VetaFilm™, which enable the creation of next-generation pharmaceutical products designed to address unmet medical needs. Its innovative product pipeline offers significant benefits for patients and physicians across various therapeutic conditions. Beyond its proprietary technologies, Nualtis provides comprehensive pharmaceutical services to partners, encompassing R&D, analytical method development, clinical monitoring, intellectual property, and regulatory support. The company also operates a state-of-the-art manufacturing facility capable of full-service production from lab-scale to pilot and commercial volumes.
The acquisition is a strategic move for Cosciens Biopharma Inc., aiming to enhance its existing biopharmaceutical development and manufacturing framework. By incorporating Nualtis' advanced film technologies and extensive service offerings, Cosciens Biopharma Inc. will strengthen its ability to innovate in drug delivery and expand its product portfolio. This integration is anticipated to create a more robust platform for developing and commercializing novel pharmaceutical solutions.
The combined entity is positioned to accelerate the development of new therapies and broaden its market presence. This strategic alignment is expected to provide pharmaceutical partners with an expanded suite of integrated services, from drug discovery and development through to advanced delivery systems and commercial-scale manufacturing, ultimately benefiting patients with improved treatment options.